D-1073-2019 Class I Terminated

Recalled by Pfizer Inc. — New York, NY

FDA drug recall D-1073-2019 was initiated by Pfizer Inc. on March 15, 2019 and is designated Class I. Reason for recall: Presence of Particulate Matter; glass particulates The recall status is terminated (terminated January 27, 2021). Affected quantity: 283,400 vials.

Recall Details

Product Type
Drugs
Report Date
April 10, 2019
Initiation Date
March 15, 2019
Termination Date
January 27, 2021
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
283,400 vials

Product Description

8.4% Sodium Bicarbonate Injection, USP 50 mEq (1 mEq/mL) 4.2 grams (84 mg/mL) 50 mL Single-dose fliptop vial, 25 vials per carton, Rx only Hospira, Inc. Lake Forest, IL 60045 USA ---- NDC 0409-6625-02

Reason for Recall

Presence of Particulate Matter; glass particulates

Distribution Pattern

United States and Puerto Rico

Code Information

Lots: 79-238-EV Exp. 1 July 2019; 79-240-EV Exp. 1 July 2019; 80-088-EV Exp. 1 August 2019